Honokiol Ameliorates Post-Myocardial Infarction Heart Failure Through Ucp3-Mediated Reactive Oxygen Species Inhibition

Abstract

Post-myocardial infarction heart failure (post-MI HF) is one of the leading global causes of death, and current prevention and treatment methods still cannot avoid the increasing incidence. Honokiol (HK) has previously been reported to improve myocardial ischemia/reperfusion injury and reverse myocardial hypertrophy by activating Sirt1 and Sirt3. We suspect that HK may also have a therapeutic effect on post-MI HF. In this study, we aimed to investigate the efficacy and mechanism of HK in the treatment of post-MI HF. We found that HK inhibited myocardial reactive oxygen species (ROS) production, reduced myocardial fibrosis, and improved cardiac function in mice after MI. HK also reduced the abnormality of mitochondrial membrane potential (MMP) and apoptosis of cardiomyocytes caused by peroxide in neonatal cardiomyocytes. RNAseq results revealed that HK restored the transcriptome changes to a certain extent and significantly enhanced the expression of mitochondrial inner membrane uncoupling protein isoform 3 (Ucp3), a protein that inhibits the production of mitochondrial ROS, protects cardiomyocytes, and relieves heart failure after myocardial infarction (MI). In cardiomyocytes with impaired Ucp3 expression, HK cannot protect against the damage caused by peroxide. More importantly, in Ucp3 knockout mice, HK did not change the increase in the ROS level and cardiac function damage after MI. Taken together, our results suggest that HK can increase the expression of the cardioprotective protein Ucp3 and maintain MMP, thereby inhibiting the production of ROS after MI and ameliorating heart failure.

Crosstalk between oxidative stress and epigenetic marks: New roles and therapeutic implications in cardiac fibrosis

“…And honokiol (HKL), a potent cardioprotectant, exerts its beneficial effects by stimulating the SIRT1/NRF2 pathway, thereby reducing OS and ameliorating myocardial injury in diabetic rats [ 41 ]. Moreover, HKL also serves as a pharmacological activator of SIRT3 [ 42 ].…”

2-APQC, a small-molecule activator of Sirtuin-3 (SIRT3), alleviates myocardial hypertrophy and fibrosis by regulating mitochondrial homeostasis

“… 33 Honokiol reduces cardiac hypertrophy by activating SIRT3. 69 However, the therapeutic effects of magnolol on various diseases may be attributed to its antioxidant capacity of polyphenolic structures, rather than its positive regulatory ability on SIRT3. Additionally, it can reduce oxidative stress and apoptosis by activating the SIRT1-nuclear factor erythroid 2-related factor 2 signaling pathway.…”

The development of nanocarriers for natural products

“…Hence, plant‐derived compounds provide pivotal insights and a repository of materials for nanocarrier design in three distinct modalities: Grafting of plant bioactive compounds into nanocarriers: combining plant bioactive compounds within nanocarriers through diverse chemical bonds augments the nanocarriers' functionalities, including biostability, drug EE, and targeted delivery precision (Abdel‐Halim et al, 2011; Joram Mendoza et al, 2020; Liang et al, 2014). Self‐assembly of plant bioactive compounds into nanostructures: based on the inherent bioactivity and polymeric self‐aggregating characteristics of various plant compounds, they can self‐assemble into nanostructures under specific conditions, serving as drug carriers or directly as pharmacodynamically active agents (Z. Li, Xu, et al, 2023; S. Liu, Tang, et al, 2022). Biomimetic nanocarriers from plant supramolecules: for instance, plant polysaccharides, proteins, and phospholipid bilayer vesicles can be meticulously extracted and exploited as nanocarriers, facilitating effective in vivo drug conveyance (Dad et al, 2021; Gong et al, 2022; Hadidi et al, 2023; Nguyen et al, 2023).…”